Verastem, Inc. (VSTM)
NASDAQ: VSTM · Real-Time Price · USD
7.49
-0.01 (-0.13%)
At close: Apr 25, 2025, 4:00 PM
7.46
-0.03 (-0.40%)
After-hours: Apr 25, 2025, 5:52 PM EDT
Verastem Revenue
In the year 2024, Verastem had annual revenue of $10.00M.
Revenue (ttm)
$10.00M
Revenue Growth
n/a
P/S Ratio
26.78
Revenue / Employee
$128,205
Employees
78
Market Cap
386.17M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
VSTM News
- 2 days ago - Verastem Oncology Announces $75 million Private Placement - Business Wire
- 4 days ago - Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors - Business Wire
- 17 days ago - Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination - Seeking Alpha
- 20 days ago - Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 - Business Wire
- 5 weeks ago - Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates - Business Wire
- 2 months ago - Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer - Business Wire
- 3 months ago - Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference - Business Wire